**Table 1: RELATIONSHIP BETWEEN OUTCOME AND PREDICTIVE FACTORS**

|  |  |  |
| --- | --- | --- |
| **VARIABLE** | **OUTCOME** | **P-value** |
| Return to baseline | Neurological disability | Death |
| n=33 (44%) | n=31 (41%) | n=11 (15%) |
| **Etiology:** n (%) |   |   |   | 0.021 |
| Acute symptomatic | 13 (17.3%) | 18 (23.8%) | 6 (8.2%) | 0.52 |
| Remote symptomatic | 4 (5.3%) | 0 | 0 |  |
| Acute on remote symptomatic | 0 | 1 (1.3%) | 2 (2.8%) |  |
| Progressive encephalopathy | 10 (13.4%) | 7 (9.3%) | 2 (2.8%) | 0.51 |
| Static encephalopathy | 4 (5.3%) | 5 (6.6%) | 0 |  |
| Idiopathic epilepsy | 2 (2.7%) | 0 | 0 |  |
| Unclassified | 0 | 0 | 1(1.2%) |  |
| **Duration of Refractory Status Epilepticus:** n (%) |  |  |  | 0.041 |
| < 24 hours | 13 (17.3%) | 4 (5.3%) | 2 (2.7%) |  |
| 24-48 hours | 8 (10.7%) | 5 (6.7%) | 1 (1.4%) |  |
| 48-72 hours | 5 (6.7%) | 8 (10.5%) | 1 (1.4%) |  |
| 72-96 hours | 4 (5.3%) | 6 (8%) | 1 (1.4%) |  |
| 96 hours | 3 (4%) | 8 (10.5%) | 6 (8.1%) |  |
| **Mean time between onset of seizures to 1st Benzodiazepine injection:** n (%) |  |  |  |  0.530 |
| < 10 minutes | 7 (9.4%) | 4 (5.4%) | 0 |   |
| 10-30 minutes | 13 (17.3%) | 13 (17.1%) | 5 (6.8%) |   |
| >30 minutes | 13 (17.3%) | 14 (18.5%) | 6 (8.2%) |   |
|  |  |  |  |  |

**Table 2: RELATIONSHIP OF ETIOLOGY WITH AGE AND SEIZURE TYPE**

|  |  |  |
| --- | --- | --- |
| **Etiology** | **Age in groups (n=75)** | **P-value** |
| 1 month - 2 years | >2 years-6 years | >6 years-12 years | >12 years-18 years |
|   |  |  |  |  | <0.01 |
| Acute symptomatic | 13 (17.4%) | 16 (21.3%) | 8 (10.7%) | 0 |
| Remote symptomatic | 1 (1.3%) | 1 (1.3%) | 0 | 2 (2.7%) |
| Acute on remote  | 1 (1.3%) | 1 (1.3%) | 1 (1.3%) | 0 |
| Progressive encephalopathy | 8 (10.7%) | 4 (5.4%) | 7 (9.3%) | 0 |
| Static encephalopathy | 6 (8%) | 3 (4%) | 0 | 0 |
| Idiopathic epilepsy | 2 (2.7%) | 0 | 0 | 0 |
| Unclassified | 1 (1.3%) | 0 | 0 | 0 |
|   |  |  |  |  |
|   | **Seizure type (n=75)** |   |
| Generalized | Focal | Mixed | Focal with bilateral tonic clonic |
|   |  |  |  |  | <0.01 |
| Acute symptomatic | 27 (36%) | 3 (4%) | 0 | 7 (9.3%) |
| Remote symptomatic | 0 | 4 (5.3%) | 0 | 0 |
| Acute on remote  | 0 | 0 | 0 | 3 (4%) |
| Progressive encephalopathy | 8 (10.7%) | 6 (8%) | 2 (2.7%) | 3 (4%) |
| Static encephalopathy | 5 (6.8%) | 0 | 1 (1.3%) | 3 (4%) |
| Idiopathic epilepsy | 0 | 1 (1.3%) | 0 | 1 (1.3%) |
| Unclassified | 0 | 0 | 0 | 1 (1.3%) |
|   |  |  |  |  |
|   |  |  |  |  |

 **Figure 1: OUTCOME Figure 2: DISABILITY GRADES**